| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000015550 |
| Receipt No. | R000018067 |
| Official scientific title of the study | Phase I trial of definitive chemoprotontherapy in patients with clinical stage IB/II/III esophageal carcinoma |
| Date of disclosure of the study information | 2014/10/28 |
| Last modified on | 2016/11/02 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Phase I trial of definitive chemoprotontherapy in patients with clinical stage IB/II/III esophageal carcinoma | |
| Title of the study (Brief title) | EC-CPT-P1 | |
| Region |
|
|
| Condition | ||||
| Condition | Esophageal Cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To determine the recommended dose of proton beam therapy for esophageal cancer concurrently with chemotherapy of CDDP and 5-FU |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | Proportion of dose limiting toxicity |
| Key secondary outcomes | Adverse event, Complete response rate |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Proton beam therapy concurrently with chemotherapy | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histologically proven squamous cell carcinoma or adenosquamous cell carcinoma
2) Primary lesion are located within the thoracic esophagus 3) Clinical stage IB or II or III (non-T4) 4) Aged 20 to 75 years old 5) ECOG PS of 0 or1 6) adequate organ functions 7) no previous treatment of esophageal cancer except EMR or ESD 8) no previous chemotherapy or radiotherapy against any other malignancies 9) written informed consent |
|||
| Key exclusion criteria | 1. Active double cancer
2. Active infection 3. Body temperature is under 38 centigrade 4. Possible pregnancy 5. Severe psychological disease 6. Systemic steroid user 7. Positive HBs antigen 8. Uncontrolled diabetes 9. Uncontrolled hypertension 10. Unstable angina, cardiac infarction within 6 months before enrollment 11. Interstitial pneumonitis, pulmonary fibrosis, severe emphysema, heart failure 12. Cerebrovascular disease within 6 months before enrollment 13. History of iodine allergy |
|||
| Target sample size | 12 | |||
| Research contact person | |
| Name of lead principal investigator | Tetsuo Akimoto |
| Organization | National Cancer Center Hospital East |
| Division name | Radation oncology Division |
| Address | 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan |
| TEL | 04-7133-1111 |
| takimoto@east.ncc.go.jp | |
| Public contact | |
| Name of contact person | Masakatsu Onozawa |
| Organization | National Cancer Center Hospital East |
| Division name | Radation oncology Division |
| Address | 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan |
| TEL | 04-7133-1111 |
| Homepage URL | |
| maonozaw@east.ncc.go.jp | |
| Sponsor | |
| Institute | National Cancer Center Hospital East |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Cancer Center Hospital East |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立研究開発法人 国立がん研究センター東病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000018067 |